Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, priced 5.0 million shares at $7 Wednesday. UBS Investment Bank and SG Cowen were the joint book runners on the deal. The stock now trades on the NASDAQ under the symbol...read more
Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, now intends to offer 5.0 million shares at a range of $7 to $9. The company originally planned to offer 6.25 million shares at a range of $11 to $13. UBS Investment Bank...read more
Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, such as a flu vaccine patch, announced Monday that it will offer 6.3 million shares at a range of $11 to $13. Assuming the stock prices at the midpoint, the company will...read more
Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, registered for an initial public offering Monday morning. The Maryland-based company has three product candidates in Phase I or II testing. UBS Investment Bank and SG Cowen ...read more
Biotech Iomai Corporation prices at $7
Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, priced 5.0 million shares at $7 Wednesday. UBS Investment Bank and SG Cowen were the joint book runners on the deal. The stock now trades on the NASDAQ under the symbol...read more
Biotech Iomai Corporation lowers range, offering size
Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, now intends to offer 5.0 million shares at a range of $7 to $9. The company originally planned to offer 6.25 million shares at a range of $11 to $13. UBS Investment Bank...read more
Vaccine maker Iomai Corporation sets terms
Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, such as a flu vaccine patch, announced Monday that it will offer 6.3 million shares at a range of $11 to $13. Assuming the stock prices at the midpoint, the company will...read more
Biopharmaceutical company Iomai Corporation files for IPO
Iomai Corporation, a developer of vaccines and immunostimulants delivered to the skin, registered for an initial public offering Monday morning. The Maryland-based company has three product candidates in Phase I or II testing. UBS Investment Bank and SG Cowen ...read more